News

The phase Ib/II proof-of-concept trial will examine PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade (bortezomib) for the treatment of relapsed, refractory multiple myeloma,

Originally the FDA decision on whether to allow the companies to re-launch Tysabri was due in March 2006. This date has now been put back to June 28,

The International Clinical Research Center (ICRC) Brno, Czech Republic project was approved by the government of the Czech Republic on March 8, 2006 with a commitment of $60

Wyeth announced that the jury in the cases of Joyce Townley versus Wyeth and Pamela Williams versus Wyeth in the Philadelphia Court of Common Pleas found in favor

The decision was based on conclusions from an outside advisory panel’s review of Nabi Biopharmaceuticals’ assessment of the StaphVAX confirmatory phase III clinical study results. The assessment revealed

There were three dose levels in the study, namely 300mg, 700mg and 1,000mg and results were measured according to American College of Rheumatology (ACR) criteria. In the 300mg

The supplemental new drug application (sNDA) was filed by United Therapeutics in satisfaction of the FDA’s Subpart H accelerated approval requirement for a phase IV post-marketing study to

The research will focus on controlling the immune system to minimize rejection of stem cell therapies introduced into the body. This may enable the successful engraftment of stem

Diamyd was formed from the merger of Pittsburgh’s Nurel Therapeutics and Diamyd Medical, a publicly traded firm based in Sweden. The company is developing a gene-based therapy that